Korro Bio, Inc. Financials
This page shows Korro Bio, Inc. (KRRO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Korro Bio’s dominant business mechanic is clinical-stage cash consumption, with research spend far ahead of still-small reported revenue.
The sharp cash decline came from a financing air pocket, not just operating burn: FY2024 brought in$69.4M of financing cash, while FY2025 brought only$685K . With free cash flow burn still near-$79.1M , cash fell to$21.8M , showing how dependent the balance sheet had been on external funding rather than internal cash generation.
This is still a science-first cost structure: FY2025 R&D ran at
Cash losses were less severe than accounting losses, with net loss at
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Korro Bio, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Korro Bio, Inc. scores -5.77, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($176.7M) relative to total liabilities ($62.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Korro Bio, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Korro Bio, Inc. generates $0.67 in operating cash flow (-$78.6M OCF vs -$117.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Korro Bio, Inc. generated $6.4M in revenue in fiscal year 2025. This represents an increase of 181.5% from the prior year.
Korro Bio, Inc.'s EBITDA was -$117.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 33.1% from the prior year.
Korro Bio, Inc. reported -$117.3M in net income in fiscal year 2025. This represents a decrease of 40.3% from the prior year.
Korro Bio, Inc. earned $-12.48 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 33.2% from the prior year.
Cash & Balance Sheet
Korro Bio, Inc. generated -$79.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 1.4% from the prior year.
Korro Bio, Inc. held $21.8M in cash against $0 in long-term debt as of fiscal year 2025.
Korro Bio, Inc. had 9M shares outstanding in fiscal year 2025. This represents an increase of 0.4% from the prior year.
Margins & Returns
Korro Bio, Inc.'s operating margin was -1906.4% in fiscal year 2025, reflecting core business profitability. This is up 2140.8 percentage points from the prior year.
Korro Bio, Inc.'s net profit margin was -1834.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1845.9 percentage points from the prior year.
Korro Bio, Inc.'s ROE was -228.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 175.9 percentage points from the prior year.
Capital Allocation
Korro Bio, Inc. invested $65.6M in research and development in fiscal year 2025. This represents an increase of 3.0% from the prior year.
Korro Bio, Inc. invested $518K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 97.1% from the prior year.
KRRO Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $1.3M+18.5% | $1.1M-25.3% | $1.5M-42.7% | $2.5M | N/A | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $13.0M+17.9% | $11.0M-20.5% | $13.8M-34.3% | $21.0M+6.5% | $19.7M | N/A | $16.0M-6.9% | $17.1M |
| SG&A Expenses | $7.5M+20.9% | $6.2M-4.9% | $6.5M-14.7% | $7.6M-2.6% | $7.8M | N/A | $7.3M+4.9% | $7.0M |
| Operating Income | -$20.4M+59.4% | -$50.4M-162.0% | -$19.2M+29.3% | -$27.2M-8.7% | -$25.0M | N/A | -$23.3M+3.5% | -$24.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $95K-85.1% | $636K | $0-100.0% | $1K | $0 | N/A | -$9K-130.0% | $30K |
| Net Income | -$19.6M+60.8% | -$50.0M-177.1% | -$18.1M+29.9% | -$25.8M-10.2% | -$23.4M | N/A | -$21.0M+3.8% | -$21.8M |
| EPS (Diluted) | $-1.69 | N/A | $-1.92+29.9% | $-2.74-10.0% | $-2.49 | N/A | $-2.26+7.0% | $-2.43 |
KRRO Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $183.6M+61.8% | $113.5M-29.7% | $161.6M-10.5% | $180.4M-10.8% | $202.2M-10.6% | $226.2M-7.1% | $243.5M-2.4% | $249.6M |
| Current Assets | $120.2M+45.9% | $82.4M-16.1% | $98.2M-4.3% | $102.6M-15.3% | $121.2M-7.8% | $131.5M-13.9% | $152.8M-6.6% | $163.6M |
| Cash & Equivalents | $61.7M+182.7% | $21.8M-9.7% | $24.2M-28.1% | $33.6M-47.6% | $64.1M+15.3% | $55.6M-12.0% | $63.2M-30.7% | $91.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $64.0M+3.1% | $62.1M-0.7% | $62.5M-4.3% | $65.3M+3.3% | $63.3M-3.9% | $65.8M+3.0% | $63.9M+24.1% | $51.5M |
| Current Liabilities | $14.8M+23.9% | $11.9M-18.5% | $14.6M-14.8% | $17.2M+33.3% | $12.9M-13.9% | $15.0M+9.9% | $13.6M+10.4% | $12.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $119.6M+132.6% | $51.4M-48.1% | $99.0M-14.0% | $115.1M-17.2% | $139.0M-13.4% | $160.4M-10.7% | $179.6M-9.3% | $198.1M |
| Retained Earnings | -$403.5M-5.1% | -$383.8M-15.0% | -$333.8M-5.7% | -$315.7M-8.9% | -$290.0M-8.8% | -$266.6M-8.6% | -$245.4M-9.4% | -$224.4M |
KRRO Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16.1M+9.2% | -$17.7M-3.0% | -$17.2M+10.7% | -$19.2M+21.4% | -$24.5M-226.2% | -$7.5M+53.4% | -$16.1M-10.3% | -$14.6M |
| Capital Expenditures | $21K-75.0% | $84K-52.0% | $175K+25.0% | $140K+17.6% | $119K-91.8% | $1.5M-70.2% | $4.9M-18.2% | $6.0M |
| Free Cash Flow | -$16.1M+9.5% | -$17.8M-2.5% | -$17.4M+10.4% | -$19.4M+21.2% | -$24.6M-174.6% | -$8.9M+57.3% | -$21.0M-2.0% | -$20.6M |
| Investing Cash Flow | -$32.2M-316.1% | $14.9M+96.4% | $7.6M+167.2% | -$11.3M-134.5% | $32.8M+1285.6% | -$2.8M+78.0% | -$12.6M+87.7% | -$102.4M |
| Financing Cash Flow | $88.2M+23113.7% | $380K+196.9% | $128K+2460.0% | $5K-97.1% | $172K-81.5% | $932K+28.0% | $728K-98.9% | $67.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
KRRO Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -801.4%+3099.2pp | -3900.6%-2135.8pp | -1764.9%+98.3pp | -1863.1%-882.0pp | -981.2% | N/A | N/A | N/A |
| Net Margin | -769.6%+3103.6pp | -3873.2%-2216.3pp | -1657.0%+108.1pp | -1765.1%-847.9pp | -917.1% | N/A | N/A | N/A |
| Return on Equity | -16.4%+80.9pp | -97.3%-79.0pp | -18.2%+4.1pp | -22.4%-5.6pp | -16.8% | N/A | -11.7%-0.7pp | -11.0% |
| Return on Assets | -10.7%+33.4pp | -44.1%-32.9pp | -11.2%+3.1pp | -14.3%-2.7pp | -11.6% | N/A | -8.6%+0.1pp | -8.7% |
| Current Ratio | 8.13+1.2 | 6.90+0.2 | 6.71+0.7 | 5.98-3.4 | 9.41+0.6 | 8.79-2.4 | 11.23-2.1 | 13.28 |
| Debt-to-Equity | 0.53-0.7 | 1.21+0.6 | 0.63+0.1 | 0.57+0.1 | 0.46+0.0 | 0.41+0.1 | 0.36+0.1 | 0.26 |
| FCF Margin | -631.2%+745.4pp | -1376.6%+215.5pp | -1592.1%-265.5pp | -1326.6%-363.0pp | -963.6% | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Korro Bio, Inc.'s annual revenue?
Korro Bio, Inc. (KRRO) reported $6.4M in total revenue for fiscal year 2025. This represents a 181.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Korro Bio, Inc.'s revenue growing?
Korro Bio, Inc. (KRRO) revenue grew by 181.5% year-over-year, from $2.3M to $6.4M in fiscal year 2025.
Is Korro Bio, Inc. profitable?
No, Korro Bio, Inc. (KRRO) reported a net income of -$117.3M in fiscal year 2025, with a net profit margin of -1834.5%.
What is Korro Bio, Inc.'s EBITDA?
Korro Bio, Inc. (KRRO) had EBITDA of -$117.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Korro Bio, Inc.'s operating margin?
Korro Bio, Inc. (KRRO) had an operating margin of -1906.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Korro Bio, Inc.'s net profit margin?
Korro Bio, Inc. (KRRO) had a net profit margin of -1834.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Korro Bio, Inc.'s return on equity (ROE)?
Korro Bio, Inc. (KRRO) has a return on equity of -228.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Korro Bio, Inc.'s free cash flow?
Korro Bio, Inc. (KRRO) generated -$79.1M in free cash flow during fiscal year 2025. This represents a -1.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Korro Bio, Inc.'s operating cash flow?
Korro Bio, Inc. (KRRO) generated -$78.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Korro Bio, Inc.'s total assets?
Korro Bio, Inc. (KRRO) had $113.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Korro Bio, Inc.'s capital expenditures?
Korro Bio, Inc. (KRRO) invested $518K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Korro Bio, Inc. spend on research and development?
Korro Bio, Inc. (KRRO) invested $65.6M in research and development during fiscal year 2025.
What is Korro Bio, Inc.'s current ratio?
Korro Bio, Inc. (KRRO) had a current ratio of 6.90 as of fiscal year 2025, which is generally considered healthy.
What is Korro Bio, Inc.'s debt-to-equity ratio?
Korro Bio, Inc. (KRRO) had a debt-to-equity ratio of 1.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Korro Bio, Inc.'s return on assets (ROA)?
Korro Bio, Inc. (KRRO) had a return on assets of -103.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Korro Bio, Inc.'s cash runway?
Based on fiscal year 2025 data, Korro Bio, Inc. (KRRO) had $21.8M in cash against an annual operating cash burn of $78.6M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Korro Bio, Inc.'s Altman Z-Score?
Korro Bio, Inc. (KRRO) has an Altman Z-Score of -5.77, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Korro Bio, Inc.'s Piotroski F-Score?
Korro Bio, Inc. (KRRO) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Korro Bio, Inc.'s earnings high quality?
Korro Bio, Inc. (KRRO) has an earnings quality ratio of 0.67x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Korro Bio, Inc.?
Korro Bio, Inc. (KRRO) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.